FAKZYNJA

Verastem Oncology (VSTM) plans a public offering of common stock, granting underwriters a 30-day option for 15% more shares. Jefferies, Guggenheim Securities, and Cantor are joint book-running managers. Net proceeds will support the commercialization of AVMAPKI™ FAKZYNJA™ CO-PACK for KRAS-mutated recurrent Low-Grade Serous Ovarian Cancer and clinical development, including the VS-7375 oral KRAS G12D inhibitor, and general corporate needs. The offering depends on market conditions. A shelf registration statement is effective, and offering documents are available on the SEC website.